Browse

The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.

Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.

The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.